Shire Owners | StatInvestor

Health Care & Life Sciences » Pharmaceuticals | Shire PLC

Shire PLC | Ownership

Companies that own Shire PLC

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

Aberdeen Asset Investments Ltd.

31,244,301

3.42%

22,287

3.72%

09/10/2018

Capital Research & Management Co. (World Investors)

30,862,350

3.38%

1,581,850

0.25%

06/30/2018

The Vanguard Group, Inc.

30,247,369

3.31%

-62,457

0.06%

09/10/2018

State Street Global Advisors Ltd.

23,539,159

2.57%

943,267

1.54%

09/10/2018

Legal & General Investment Management Ltd.

21,131,243

2.31%

1,184

0.56%

09/10/2018

Norges Bank Investment Management

20,413,104

2.23%

17,828

0.17%

09/07/2018

Fidelity Management & Research Co.

18,875,653

2.06%

-6,784

0.11%

09/10/2018

Glenview Capital Management LLC

15,794,769

1.73%

909,072

5.48%

07/31/2018

Lazard Asset Management LLC

13,972,211

1.53%

-222,672

0.77%

09/10/2018

FIL Investment Advisors (UK) Ltd.

12,366,353

1.35%

-1,480,342

0.74%

07/31/2018

About Shire

View Profile

Address	4-1-1 Dosho-machi Osaka Osaka 540 Japan
Employees	-
Website	http://www.takeda.co.jp
Updated	07/08/2019
Shire Plc is a biopharmaceutical company. It engaged in the research, development, licensing, manufacturing, marketing, distribution and sale of medicines to meet significant unmet patient needs. The company's products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr and foznol.